Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in

Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.

European urology. 2021 Mar 12 [Epub ahead of print]

Christian Daniel Fankhauser, Jan Oldenburg, Peter Albers, Ferran Algaba, Carsten Bokemeyer, Joost L Boormans, Stefanie Fischer, Karim Fizazi, Hendrik Gremmels, Javier Mayor de Castro, Florian Janisch, Tim Muilwijk, Ricardo Leão, David Nicol, Nicola Nicolai, Torgrim Tandstad, M Pilar Laguna

Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland. Electronic address: ., Department of Oncology, Oslo University Hospital, Oslo, Norway., Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany., Department of Pathology, Fundacio Puigvert, Barcelona, Spain., Department of Oncology, Hematology and Bone Marrow Transplantation with Pneumology Section, Universitätskliniken Eppendorf, Hamburg, Germany., Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., European Association of Urology Guidelines Office, Arnhem, The Netherlands., Department of Urology, Hospital Gregorio Marañón, Madrid, Spain., Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Department of Urology, University Hospitals Leuven, Leuven, Belgium., Department of Urology, Faculty of Medicine, University of Coimbra, Clinical Academic Center of Coimbra, Coimbra, Portugal., Department of Urology, The Royal Marsden NHS Foundation Trust, London, UK., Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Department of Oncology, The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway., Department of Urology Medipol Mega, Istanbul Medipol University, Istanbul, Turkey.